Stewart W C, Castelli W P
Department of Ophthalmology, Medical University of South Carolina, Charleston 29425-2236, USA.
Clin Cardiol. 1996 Sep;19(9):691-7. doi: 10.1002/clc.4960190904.
Glaucoma, a disease that affects between 1 and 3% of the population above the age of 60, is most commonly treated by topical beta-adrenergic blockers. Although effective in lowering intraocular pressure and helping to preserve sight, beta blockers also may have adverse influences on the cardiac, pulmonary, and central nervous systems, and on endocrine functions. Clinicians' awareness that their patients may be treated with topical beta blockers will help them to elicit this information and the history, prescribe the medicine correctly, and be cognizant of a possible role this medicine may have in any deterioration of a patient's systemic clinical status.
青光眼是一种影响60岁以上人群1%至3%的疾病，最常用局部β-肾上腺素能阻滞剂进行治疗。β受体阻滞剂虽然在降低眼压和帮助保护视力方面有效，但也可能对心脏、肺、中枢神经系统以及内分泌功能产生不利影响。临床医生意识到他们的患者可能会接受局部β受体阻滞剂治疗，这将有助于他们获取此类信息和病史，正确开药，并认识到这种药物可能在患者全身临床状况恶化中所起的作用。
